For brain metastasis in NSCLC, the EGFR-tyrosine kinase inhibitor gefitinib combined with venetoclax or navitoclax showed appreciable synergistic effects against NSCLC tumors and was expected to overcome gefitinib-induced resistance [149]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.